Alcyone Therapeutics In Collaboration With Biogen, Announced That The FDA Has Approved A Pivotal Trial Of Alcyone's ThecaFlex DRx System To Assess Repeat Intrathecal Access, Cerebrospinal Fluid Aspiration, And Delivery Of Spinraza (Nusinersen)
Portfolio Pulse from Benzinga Newsdesk
Alcyone Therapeutics announced a collaboration with Biogen for a pivotal FDA-approved trial of Alcyone's ThecaFlex DRx System to assess repeat intrathecal access, cerebrospinal fluid aspiration, and delivery of Spinraza (Nusinersen).
June 27, 2023 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen is collaborating with Alcyone Therapeutics for an FDA-approved trial of Alcyone's ThecaFlex DRx System, which may enhance the delivery of Biogen's Spinraza.
The collaboration between Biogen and Alcyone Therapeutics for the FDA-approved trial of ThecaFlex DRx System may lead to improved delivery of Spinraza, a key product for Biogen. This partnership and regulatory approval could positively impact Biogen's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90